Mild clinical manifestations of SARS-CoV-2 related pneumonia in two patients with multiple sclerosis under treatment with ocrelizumab

•Ocrelizumab is not associated to increased severity in MS patients with COVID-19.•B-cell depleting treatment could impact on virus-specific antibody production.•B-cell depleting therapies can reduce IL-6 production, thus modulating inflammation. Recently SARS-CoV-2 has spread worldwide causing a pa...

Full description

Saved in:
Bibliographic Details
Published in:Multiple sclerosis and related disorders 2020-10, Vol.45, p.102442-102442, Article 102442
Main Authors: Iannetta, Marco, Cesta, Novella, Stingone, Christof, Malagnino, Vincenzo, Teti, Elisabetta, Vitale, Pietro, De Simone, Giuseppe, Rossi, Benedetta, Ansaldo, Lorenzo, Compagno, Mirko, Spalliera, Ilaria, Di Lorenzo, Andrea, Landi, Doriana, Nicoletti, Carolina Gabri, Marfia, Girolama Alessandra, Andreoni, Massimo, Sarmati, Loredana
Format: Article
Language:English
Subjects:
Adult
Antibodies, Monoclonal, Humanized - therapeutic use
Betacoronavirus
Coronavirus Infections - complications
Coronavirus Infections - immunology
Correspondence
COVID-19
Disease modifying therapies
DMD
DMT
Female
Humans
IL-6
Immunocompromised Host
Immunologic Factors - therapeutic use
Male
Middle Aged
Multiple Sclerosis - complications
Multiple Sclerosis - drug therapy
Pandemics
Pneumonia - immunology
Pneumonia - virology
Pneumonia, Viral - complications
Pneumonia, Viral - immunology
SARS-CoV-2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Ocrelizumab is not associated to increased severity in MS patients with COVID-19.•B-cell depleting treatment could impact on virus-specific antibody production.•B-cell depleting therapies can reduce IL-6 production, thus modulating inflammation. Recently SARS-CoV-2 has spread worldwide causing a pandemic. Little is known about disease severity in immunocompromised hosts and people receiving disease modifying therapies (DMTs). In the last decades DMTs have been widely employed, and ocrelizumab represents one of the newest therapies for the relapsing remitting and progressive forms of multiple sclerosis (MS). to describe SARS-CoV-2 related pneumonia in two MS patients under ocrelizumab treatment. Case series. Patients showed a mild clinical course of SARS-CoV-2 related pneumonia without complications or sequelae. Ocrelizumab treatment is not necessarily associated to increased severity in MS patients with SARS-CoV-2 infection.
ISSN:2211-0348
2211-0356
DOI:10.1016/j.msard.2020.102442